DOCSLIB.ORG

Azithromycin to Prevent Pseudomonas Aeruginosa Ventilator-Associated Pneumonia by Inhibition of Quorum Sensing: a Randomized Controlled Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Azithromycin to Prevent Pseudomonas Aeruginosa Ventilator-Associated Pneumonia by Inhibition of Quorum Sensing: a Randomized Controlled Trial Article Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial VAN DELDEN, Christian, et al. Abstract Anti-virulence strategies have not been evaluated for the prevention of bacterial infections. Prolonged colonization of intubated patients with Pseudomonas aeruginosa isolates producing high-levels of the quorum sensing (QS)-regulated virulence factor rhamnolipids has been associated with ventilator-associated pneumonia (VAP). In this pathogen, azithromycin reduces QS-regulated virulence. We aimed to assess whether azithromycin could prevent VAP in patients colonized by rhamnolipids producing isolates. Reference VAN DELDEN, Christian, et al. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Medicine, 2012, vol. 38, no. 7, p. 1118-25 DOI : 10.1007/s00134-012-2559-3 PMID : 22527075 Available at: http://archive-ouverte.unige.ch/unige:32040 Disclaimer: layout of this document may differ from the published version. 1 / 1 Intensive Care Med (2012) 38:1118–1125 DOI 10.1007/s00134-012-2559-3 ORIGINAL Christian van Delden Azithromycin to prevent Pseudomonas Thilo Ko¨hler Franc¸oise Brunner-Ferber aeruginosa ventilator-associated pneumonia Bruno Franc¸ois Jean Carlet by inhibition of quorum sensing: a randomized Jean-Claude Peche`re controlled trial F. Brunner-Ferber at the highest risk to develop VAP Received: 8 June 2011 Brunner Naga, Pfaeffikon-ZH, Accepted: 29 February 2012 linked to this QS-dependent virulence Switzerland Published online: 20 April 2012 factor. Results: Ninety-two patients Ó Copyright jointly held by Springer and were enrolled; 43 azithromycin-trea- ESICM 2012 B. Franc¸ois Intensive Care Unit, CIC-P 0801 Inserm, ted and 42 placebo patients were Presented in part at the ICAAC meeting Dupuytren Hospital Limoges, eligible for the per-protocol analysis. 2010 Boston. Limoges, France In the per-protocol population, the occurrence of P. aeruginosa VAP This article is discussed in the editorial J. Carlet was reduced in the azithromycin available at: Groupe Hospitalier Saint Joseph, doi:10.1007/s00134-012-2561-9. group but without reaching statistical Paris, France significance (4.7 vs. 14.3 % VAP, J.-C. Peche`re: Deceased 29th November 2008. p = 0.156). QS-dependent virulence Abstract Purpose: Anti-virulence of colonizing isolates was similarly Electronic supplementary material strategies have not been evaluated for low in both study groups, and only The online version of this article the prevention of bacterial infections. five patients in each arm were per- (doi:10.1007/s00134-012-2559-3) contains supplementary material, which is available Prolonged colonization of intubated sistently colonized by high-level to authorized users. patients with Pseudomonas aerugin- rhamnolipids producing isolates. In osa isolates producing high-levels of this high-risk subgroup, the incidence the quorum sensing (QS)-regulated of VAP was reduced fivefold in virulence factor rhamnolipids has azithromycin versus placebo patients been associated with ventilator-asso- (1/5 vs. 5/5 VAP, p = 0.048). Con- ciated pneumonia (VAP). In this clusions: There was a trend towards pathogen, azithromycin reduces QS- reduced incidence of VAP in colo- regulated virulence. We aimed to nized azithromycin-treated patients. C. van Delden ()) Á T. Ko¨hler assess whether azithromycin could In addition, azithromycin signifi- Service of Infectious Diseases, prevent VAP in patients colonized by cantly prevented VAP in those University Hospital Geneva, 4 Rue Gabrielle-Perret-Gentil, rhamnolipids producing isolates. patients at high risk of rhamnolipid- 1211 Geneva, Switzerland Methods: In a randomized, double- dependent VAP, suggesting that vir- e-mail: [email protected] blind, multicenter trial, intubated ulence inhibition is a promising anti- Tel.: ?41-22-3723207 colonized patients received either microbial strategy. Fax: ?41-22-3727863 300 mg/day azithromycin or placebo. Primary endpoint was the occurrence Keywords Pseudomonas C. van Delden Á T. Ko¨hler Á J.-C. Peche`re of P. aeruginosa VAP. We further aeruginosa Á Ventilator-associated Department of Microbiology and Molecular Medicine, identified those patients persistently pneumonia Á Virulence Á Quorum University of Geneva, colonized by isolates producing high- sensing Á Rhamnolipids Geneva, Switzerland levels of rhamnolipids and therefore 1119 Introduction documented colonization in bronchial aspirates at study entry. We obtained approval for this multicenter European Multi-drug-resistant bacteria represent a major medical study by the respective local ethics committees and national threat, contributing to the deaths of increasing numbers of agencies. Written consent from all patients or their legal patients worldwide. To face this serious challenge, alter- representatives was obtained according to legal and ethical native strategies aiming at the inhibition of bacterial considerations. The study took place between November virulence have been proposed [1]. Due to the absence of 2002 and November 2005. Twenty-one European centers selective pressure, such strategies are believed to mini- participated in this trial; eight in France, four in Spain, two in mize the risk of emergence of resistant clones [2, 3]. To Belgium, three in Poland, two in Serbia, and two in Swit- our knowledge, however, no clinical study has demon- zerland. We screened mechanically ventilated patients for strated the feasibility of such an approach. respiratory tract colonization by P. aeruginosa on alternate Pseudomonas aeruginosa is a leading cause of venti- days. Eligible patients were adults between 18 and 75 years lator-associated pneumonia (VAP) [4–6]. This pathogen of age, hospitalized in the ICU under mechanical ventilation frequently develops resistance to available antimicrobial expected to be required for at least 3 days, with a reasonable agents [7–9]. Improved treatments and/or preventive surviving chance (Apache score between 10 and 25), and measures are urgently required since attributable mortal- proven to be colonized by P. aeruginosa. Neutropenic ity of this condition remains high [6]. Whereas almost all patients and patients treated with immunosuppressive drugs cases of P. aeruginosa-associated VAP are preceded by were not eligible. Patients with ongoing P. aeruginosa colonization of the respiratory tract, only 10–20 % of infection, having received macrolides or antibiotics active colonized patients eventually evolve to VAP [4]. Quorum against the colonizing P. aeruginosa isolate during the last sensing (QS) is a complex signaling network that allows 14 days were excluded. Patients with proven colonization coordinated gene expression according to cell density [1] by P. aeruginosa were randomized (D-1) and received and regulates many major virulence factors in P. aeru- either placebo or 300 mg per day iv azithromycin in a ginosa [10]. As a consequence, QS is an ideal target for double-blind fashion for a maximum of 20 days (D1 to Dx). anti-virulence strategies. Macrolides, like azithromycin, The 300-mg dose was selected taking into account a bio- are neither bactericidal nor bacteriostatic for P. aerugin- availability of 37 % of the usual 500-mg oral dose, the need osa at clinically achievable concentrations and are for reaching steady state at lung level within 3 days, and therefore unlikely to select resistant clones. However, at safety considerations. these concentrations, azithromycin inhibits QS in vitro During the study, the administration of antibiotics [11–14]. Furthermore, we have shown that azithromycin proven to be inactive against the isolated P. aeruginosa reduces the expression of QS-circuit and target genes in strains was allowed without restrictions. The adminis- patient [15]. Azithromycin has a favorable profile in tration of antibiotics with intrinsic activity against terms of pharmacokinetics and of metabolism. Lung tis- P. aeruginosa strains was only allowed if considered as sue distribution is high, enabling to reach QS-inhibitory mandatory. The prophylaxis study period was restricted to concentrations (2–4 lg/ml) in bronchial mucosa, epithe- a maximum of 20 days, and reasons for early discontin- lial lining fluid, and sputum after a single 500-mg dose uation included extubation, death, serious adverse events, [16]. No clinical trial has previously investigated a viru- or suspected P. aeruginosa VAP. The diagnosis of lence inhibition strategy for the prevention of bacterial P. aeruginosa VAP was based on the clinical picture, infections. Thus, we decided to conduct a proof-of-con- X-ray scan, a pulmonary infection score (CPIS) C6, as cept study, designed as a multicenter, randomized, well as a quantitative culture of a bronchoalveolar lavage double-blind, placebo-controlled trial to evaluate azith- fluid (BAL) yielding [104 CFU/ml P. aeruginosa, in the romycin for the prevention of P. aeruginosa VAP in absence of other pathogenic bacterial species [17, 18]. An colonized mechanically ventilated patients. independent panel of three experts blinded to treatment confirmed the P. aeruginosa VAP cases. Methods Clinical sample collection Study population Starting the first day of proven colonization (D-1), daily tracheal aspirates (usually 0.3–5 ml) and P. aeruginosa This pilot, randomized, placebo-controlled, double-blind strains were collected during the entire study period. study (ANB 006#2001, ClinicalTrials.gov
Load more

Recommended publications
  • Contemporary Clinical Trials Communications 16 (2019) 100488
    Contemporary Clinical Trials Communications 16 (2019) 100488 Contents lists available at ScienceDirect Contemporary Clinical Trials Communications journal homepage: http://www.elsevier.com/locate/conctc Opinion paper Creating an academic research organization to efficiently design, conduct, coordinate, and analyze clinical trials: The Center for Clinical Trials & Data Coordination Kaleab Z. Abebe *, Andrew D. Althouse, Diane Comer, Kyle Holleran, Glory Koerbel, Jason Kojtek, Joseph Weiss, Susan Spillane Center for Clinical Trials & Data Coordination, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA ARTICLE INFO ABSTRACT Keywords: When properly executed, the randomized controlled trial is one of the best vehicles for assessing the effectiveness Data coordinating center of one or more interventions. However, numerous challenges may emerge in the areas of study startup, Clinical trial management recruitment, data quality, cost, and reporting of results. The use of well-run coordinating centers could help prevent these issues, but very little exists in the literature describing their creation or the guiding principles behind their inception. The Center for Clinical Trials & Data Coordination (CCDC) was established in 2015 through institutional funds with the intent of 1) providing relevant expertise in clinical trial design, conduct, coordination, and analysis; 2) advancing the careers of clinical investigators and CCDC-affiliated faculty; and 3) obtaining large data coordi­ nating center (DCC) grants. We describe the organizational structure of the CCDC as well as the homegrown clinical trial management system integrating nine crucial elements: electronic data capture, eligibility and randomization, drug and external data tracking, safety reporting, outcome adjudication, data and safety moni­ toring, statistical analysis and reporting, data sharing, and regulatory compliance.
    [Show full text]
  • Adaptive Enrichment Designs in Clinical Trials
    Annual Review of Statistics and Its Application Adaptive Enrichment Designs in Clinical Trials Peter F. Thall Department of Biostatistics, M.D. Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA; email: [email protected] Annu. Rev. Stat. Appl. 2021. 8:393–411 Keywords The Annual Review of Statistics and Its Application is adaptive signature design, Bayesian design, biomarker, clinical trial, group online at statistics.annualreviews.org sequential design, precision medicine, subset selection, targeted therapy, https://doi.org/10.1146/annurev-statistics-040720- variable selection 032818 Copyright © 2021 by Annual Reviews. Abstract All rights reserved Adaptive enrichment designs for clinical trials may include rules that use in- terim data to identify treatment-sensitive patient subgroups, select or com- pare treatments, or change entry criteria. A common setting is a trial to Annu. Rev. Stat. Appl. 2021.8:393-411. Downloaded from www.annualreviews.org compare a new biologically targeted agent to standard therapy. An enrich- ment design’s structure depends on its goals, how it accounts for patient heterogeneity and treatment effects, and practical constraints. This article Access provided by University of Texas - M.D. Anderson Cancer Center on 03/10/21. For personal use only. first covers basic concepts, including treatment-biomarker interaction, pre- cision medicine, selection bias, and sequentially adaptive decision making, and briefly describes some different types of enrichment. Numerical illus- trations are provided for qualitatively different cases involving treatment- biomarker interactions. Reviews are given of adaptive signature designs; a Bayesian design that uses a random partition to identify treatment-sensitive biomarker subgroups and assign treatments; and designs that enrich superior treatment sample sizes overall or within subgroups, make subgroup-specific decisions, or include outcome-adaptive randomization.
    [Show full text]
  • Evaluating Alternative Hypotheses to Explain the Downward Trend in the Indices of the COVID-19 Pandemic Death Rate
    Evaluating alternative hypotheses to explain the downward trend in the indices of the COVID-19 pandemic death rate Sonali Shinde1, Pratima Ranade1 and Milind Watve2 1 Department of Biodiversity, Abasaheb Garware College, Pune, Pune, Maharashtra, India 2 Independent Researcher, Pune, Maharashtra, India ABSTRACT Background: In the ongoing Covid-19 pandemic, in the global data on the case fatality ratio (CFR) and other indices reflecting death rate, there is a consistent downward trend from mid-April to mid-November. The downward trend can be an illusion caused by biases and limitations of data or it could faithfully reflect a declining death rate. A variety of explanations for this trend are possible, but a systematic analysis of the testable predictions of the alternative hypotheses has not yet been attempted. Methodology: We state six testable alternative hypotheses, analyze their testable predictions using public domain data and evaluate their relative contributions to the downward trend. Results: We show that a decline in the death rate is real; changing age structure of the infected population and evolution of the virus towards reduced virulence are the most supported hypotheses and together contribute to major part of the trend. The testable predictions from other explanations including altered testing efficiency, time lag, improved treatment protocols and herd immunity are not consistently supported, or do not appear to make a major contribution to this trend although they may influence some other patterns of the epidemic. Conclusion: The fatality of the infection showed a robust declining time trend between mid April to mid November. Changing age class of the infected and Submitted 7 December 2020 Accepted 3 March 2021 decreasing virulence of the pathogen were found to be the strongest contributors to Published 20 April 2021 the trend.
    [Show full text]
  • Metabolic Sensor Governing Bacterial Virulence in Staphylococcus Aureus
    Metabolic sensor governing bacterial virulence in PNAS PLUS Staphylococcus aureus Yue Dinga, Xing Liub, Feifei Chena, Hongxia Dia, Bin Xua, Lu Zhouc, Xin Dengd,e, Min Wuf, Cai-Guang Yangb,1, and Lefu Lana,1 aDepartment of Molecular Pharmacology and bChinese Academy of Sciences Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; cDepartment of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China; dDepartment of Chemistry and eInstitute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637; and fDepartment of Basic Sciences University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58203 Edited by Richard P. Novick, New York University School of Medicine, New York, NY, and approved October 14, 2014 (received for review June 13, 2014) An effective metabolism is essential to all living organisms, in- To survive and replicate efficiently in the host, S. aureus has cluding the important human pathogen Staphylococcus aureus.To developed exquisite mechanisms for scavenging nutrients and establish successful infection, S. aureus must scavenge nutrients adjusting its metabolism to maintain growth while also coping with and coordinate its metabolism for proliferation. Meanwhile, it also stress (6, 11). On the other hand, S. aureus produces a wide array must produce an array of virulence factors to interfere with host of virulence factors to evade host immune defenses and to derive defenses. However, the ways in which S. aureus ties its metabolic nutrition either parasitically or destructively from the host during state to its virulence regulation remain largely unknown. Here we infections (6).
    [Show full text]
  • The Α7 Nicotinic Agonist ABT-126 in the Treatment
    Neuropsychopharmacology (2016) 41, 2893–2902 © 2016 American College of Neuropsychopharmacology. All rights reserved 0893-133X/16 www.neuropsychopharmacology.org The ɑ7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study ,1 1 1,2 1 George Haig* , Deli Wang , Ahmed A Othman and Jun Zhao 1 2 Abbvie Inc., North Chicago, IL, USA; Faculty of Pharmacy, Cairo University, Cairo, Egypt A double-blind, placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy and safety of 3 doses of ABT-126, an α7 nicotinic receptor agonist, for the treatment of cognitive impairment in nonsmoking subjects with schizophrenia. Clinically stable subjects were randomized in 2 stages: placebo, ABT-126 25 mg, 50 mg or 75 mg once daily (stage 1) and placebo or ABT-126 50 mg (stage 2). The primary analysis was the change from baseline to week 12 on the MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score for ABT-126 50 mg vs placebo using a mixed-model for repeated-measures. A key secondary measure was the University of California Performance-based Assessment-Extended Range (UPSA-2ER). A total of 432 subjects were randomized and 80% (344/431) completed the study. No statistically significant differences were observed in either the change from baseline for the MCCB neurocognitive composite score (+2.66 [ ± 0.54] for ABT-126 50 mg vs +2.46 [ ± 0.56] for placebo at week 12; P40.05) or the UPSA-2ER. A trend for improvement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total − ± − ± = score for ABT-126 50 mg (change from baseline 4.27 [0.58] vs 3.00 [0.60] for placebo; P 0.059).
    [Show full text]
  • Downloadable Database from January 1 to October 21, 2020
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.29.20237875; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . CLINICAL TRIALS IN COVID-19 MANAGEMENT & PREVENTION: A META-EPIDEMIOLOGICAL STUDY EXAMINING METHODOLOGICAL QUALITY Authors: Kimia Honarmand MD MSc1, Jeremy Penn BHSc (c)2, Arnav Agarwal3,4, Reed Siemieniuk3, Romina Brignardello- Petersen3, Jessica J Bartoszko3, Dena Zeraatkar3,5, Thomas Agoritsas3,6, Karen Burns3,7, Shannon M. Fernando MD MSc8, Farid Foroutan9, Long Ge PhD10, Francois Lamontagne11, Mario A Jimenez-Mora MD12, Srinivas Murthy13, Juan Jose Yepes Nuñez12,14 MD, MSc, PhD, Per O Vandvik MD, Ph.D15, Zhikang Ye3, Bram Rochwerg MD MSc3,16 Affiliations: 1. Division of Critical Care, Department of Medicine, Western University, London, Canada 2. Faculty of Health Sciences, McMaster University, Hamilton, Canada 3. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada 4. Department of Medicine, University of Toronto, Toronto, Canada 5. Department of Biomedical Informatics, Harvard Medical School, Boston, USA 6. Division General Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland 7. Unity Health Toronto, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Toronto, Canada 8. Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, Canada 9. Ted Rogers Centre for Heart Research, University Health Network, Toronto General Hospital, Toronto, Canada 10. Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China 11.
    [Show full text]
  • Studies of Staphylococcal Infections. I. Virulence of Staphy- Lococci and Characteristics of Infections in Embryonated Eggs * WILLIAM R
    Journal of Clinical Investigation Vol. 43, No. 11, 1964 Studies of Staphylococcal Infections. I. Virulence of Staphy- lococci and Characteristics of Infections in Embryonated Eggs * WILLIAM R. MCCABE t (From the Research Laboratory, West Side Veterans Administration Hospital, and the Department of Medicine, Research and Educational Hospitals, University of Illinois College of Medicine, Chicago, Ill.) Many of the determinants of the pathogenesis niques still require relatively large numbers of and course of staphylococcal infections remain staphylococci to produce infection (19). Fatal imprecisely defined (1, 2) despite their increas- systemic infections have been equally difficult to ing importance (3-10). Experimental infections produce in animals and have necessitated the in- in suitable laboratory animals have been of con- jection of 107 to 109 bacteria (20-23). A few siderable assistance in clarifying the role of host strains of staphylococci have been found that are defense mechanisms and specific bacterial virulence capable of producing lethal systemic infections factors with a variety of other infectious agents. with inocula of from 102 to 103 bacteria (24) and A sensitive experimental model would be of value have excited considerable interest (25-27). The in defining the importance of these factors in virulence of these strains apparently results from staphylococcal infections, but both humans and an unusual antigenic variation (27, 28) which, the usual laboratory animals are relatively re- despite its interest, is of doubtful significance in sistant. Extremely large numbers of staphylo- human staphylococcal infection, since such strains cocci are required to produce either local or sys- have been isolated only rarely from clinical in- temic infections experimentally.
    [Show full text]
  • Virulence During Newcastle Disease Viruses Cross Species Adaptation
    viruses Review Virulence during Newcastle Disease Viruses Cross Species Adaptation Claudio L. Afonso Base2bio, LLC, Oshkosh, WI 54905, USA; [email protected]; Tel.: +1-800-817-7160 Abstract: The hypothesis that host adaptation in virulent Newcastle disease viruses (NDV) has been accompanied by virulence modulation is reviewed here. Historical records, experimental data, and phylogenetic analyses from available GenBank sequences suggest that currently circulating NDVs emerged in the 1920–19400s from low virulence viruses by mutation at the fusion protein cleavage site. These viruses later gave rise to multiple virulent genotypes by modulating virulence in opposite directions. Phylogenetic and pathotyping studies demonstrate that older virulent NDVs further evolved into chicken-adapted genotypes by increasing virulence (velogenic-viscerotropic pathotypes with intracerebral pathogenicity indexes [ICPIs] of 1.6 to 2), or into cormorant-adapted NDVs by moderating virulence (velogenic–neurotropic pathotypes with ICPIs of 1.4 to 1.6), or into pigeon-adapted viruses by further attenuating virulence (mesogenic pathotypes with ICPIs of 0.9 to 1.4). Pathogenesis and transmission experiments on adult chickens demonstrate that chicken-adapted velogenic-viscerotropic viruses are more capable of causing disease than older velogenic-neurotropic viruses. Currently circulating velogenic–viscerotropic viruses are also more capable of replicating and of being transmitted in naïve chickens than viruses from cormorants and pigeons. These evolutionary virulence changes are consistent with theories that predict that virulence may evolve in many directions in order to achieve maximum fitness, as determined by genetic and ecologic constraints. Keywords: NDV; evolution; virulence; host adaptation Citation: Afonso, C.L. Virulence during Newcastle Disease Viruses Cross Species Adaptation.
    [Show full text]
  • Exploring the Application of a Multicenter Study Design in the Preclinical Phase of Translational Research
    Exploring the Application of a Multicenter Study Design in the Preclinical Phase of Translational Research Victoria Hunniford Thesis submitted to the University of Ottawa in partial Fulfillment of the requirements for the Master of Science in Health Systems Telfer School of Management University of Ottawa © Victoria Hunniford, Ottawa, Canada, 2019 Abstract Multicenter preclinical studies have been suggested as a method to improve potential clinical translation of preclinical work by testing reproducibility and generalizability of findings. In these studies, multiple independent laboratories collaboratively conduct a research experiment using a shared protocol. The use of a multicenter design in preclinical experimentation is a recent approach and only a handful of these studies have been published. In this thesis, I aimed to provide insight into preclinical multicenter studies by 1) systematically synthesizing all published preclinical multicenter studies; and 2) exploring the experiences of, barriers and enablers to, and the extent of collaboration within preclinical multicenter studies. In Part One, I conducted a systematic review of preclinical multicenter studies. The database searches identified 3150 citations and 13 studies met inclusion criteria. The multicenter design was applied across a diverse range of diseases including stroke, heart attack, and traumatic brain injury. The median number of centers was 4 (range 2-6) and the median sample size was 133 (range 23-384). Most studies had lower risk of bias and higher completeness of reporting than typically seen in single-centered studies. Only five of the thirteen studies produced results consistent with previous single-center studies, highlighting a central concern of preclinical research: irreproducibility and poor generalizability of findings from single laboratories.
    [Show full text]
  • Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan
    Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan Yi-Chin Fan,1 Jen-Wei Lin,1 Shu-Ying Liao, within a year (8,9), which provided an excellent opportu- Jo-Mei Chen, Yi-Ying Chen, Hsien-Chung Chiu, nity to study the transmission dynamics and pathogenicity Chen-Chang Shih, Chi-Ming Chen, of these 2 JEV genotypes. Ruey-Yi Chang, Chwan-Chuen King, A mouse model showed that the pathogenic potential Wei-June Chen, Yi-Ting Ko, Chao-Chin Chang, is similar among different JEV genotypes (10). However, Shyan-Song Chiou the pathogenic difference between GI and GIII virus infec- tions among humans remains unclear. Endy et al. report- The virulence of genotype I (GI) Japanese encephalitis vi- ed that the proportion of asymptomatic infected persons rus (JEV) is under debate. We investigated differences in among total infected persons (asymptomatic ratio) is an the virulence of GI and GIII JEV by calculating asymptomat- excellent indicator for estimating virulence or pathogenic- ic ratios based on serologic studies during GI- and GIII-JEV endemic periods. The results suggested equal virulence of ity of dengue virus infections among humans (11). We used GI and GIII JEV among humans. the asymptomatic ratio method for a study to determine if GI JEV is associated with lower virulence than GIII JEV among humans in Taiwan. apanese encephalitis virus (JEV), a mosquitoborne Jflavivirus, causes Japanese encephalitis (JE). This virus The Study has been reported in Southeast Asia and Western Pacific re- JEVs were identified in 6 locations in Taiwan during 1994– gions since it emerged during the 1870s in Japan (1).
    [Show full text]
  • E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry
    E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2018 Procedural OMB Control No. 0910-0843 Expiration Date 09/30/2020 See additional PRA statement in section 9 of this guidance. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 885-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: [email protected] http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2018 Procedural Contains Nonbinding Recommendations TABLE OF CONTENTS INTRODUCTION ...............................................................................................................
    [Show full text]
  • Labelling Requirements for Investigational Medicinal Products in Multinational Clinical Trials: Bureaucratic Cost Driver Or Added Value?
    Labelling Requirements for Investigational Medicinal Products in Multinational Clinical Trials: Bureaucratic Cost Driver or Added Value? Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels „Master of Drug Regulatory Affairs“ der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn vorgelegt von Dr. Astrid Weyermann aus Herford Bonn 2006 Dr. Astrid Weyermann Labelling requirements for IMPs in multinational CTs Betreuer und 1. Referent: H. Jopp Zweiter Referent: Dr. J. Hofer Page 2 / 71 Dr. Astrid Weyermann Labelling requirements for IMPs in multinational CTs TABLE OF CONTENTS TABLE OF CONTENTS .......................................................................................................................... 3 1 EXECUTIVE SUMMARY.................................................................................................................. 6 2 INTRODUCTION.............................................................................................................................. 7 2.1 Definitions ..................................................................................................................................... 7 2.2 Clinical Trials ................................................................................................................................ 8 2.2.1 Types of clinical trials ............................................................................................................ 8 2.2.1.1 Phases of Clinical Trials ...................................................................................................
    [Show full text]